Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Xtant Medical Holdings Inc’s stock clocked out at $0.62, down -0.83% from its previous closing price of $0.63. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 79560.0 shares were traded. XTNT stock price reached its highest trading level at $0.646 during the session, while it also had its lowest trading level at $0.61.
Ratios:
To gain a deeper understanding of XTNT’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.22 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 17.08. For the most recent quarter (mrq), Quick Ratio is recorded 1.06 and its Current Ratio is at 2.21. In the meantime, Its Debt-to-Equity ratio is 0.64 whereas as Long-Term Debt/Eq ratio is at 0.40.
Upgrades & Downgrades
In the most recent recommendation for this company, BTIG Research on December 05, 2023, initiated with a Buy rating and assigned the stock a target price of $2.
On November 15, 2018, Maxim Group reiterated its Buy rating and also upped its target price recommendation from $10 to $6.
Maxim Group reiterated its Buy rating for the stock on February 14, 2018, while the target price for the stock was revised from $18 to $10.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 10 ’25 when ORBIMED ADVISORS LLC sold 73,114,592 shares for $0.42 per share. The transaction valued at 30,708,129 led to the insider holds 0 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XTNT now has a Market Capitalization of 87460648 and an Enterprise Value of 109547648. As of this moment, Xtant’s Price-to-Earnings (P/E) ratio for their current fiscal year is 61.25, and their Forward P/E ratio for the next fiscal year is 47.33. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.66 while its Price-to-Book (P/B) ratio in mrq is 1.74. Its current Enterprise Value per Revenue stands at 0.823 whereas that against EBITDA is 10.052.
Stock Price History:
The Beta on a monthly basis for XTNT is -0.03, which has changed by 0.57500005 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, XTNT has reached a high of $0.95, while it has fallen to a 52-week low of $0.33. The 50-Day Moving Average of the stock is -12.96%, while the 200-Day Moving Average is calculated to be 2.03%.
Shares Statistics:
It appears that XTNT traded 236.89K shares on average per day over the past three months and 188540 shares per day over the past ten days. A total of 140.00M shares are outstanding, with a floating share count of 115.83M. Insiders hold about 15.69% of the company’s shares, while institutions hold 62.92% stake in the company. Shares short for XTNT as of 1763078400 were 13665 with a Short Ratio of 0.06, compared to 1760486400 on 104252. Therefore, it implies a Short% of Shares Outstanding of 13665 and a Short% of Float of 0.01.
Earnings Estimates
. The current rating of Xtant Medical Holdings Inc (XTNT) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.03 and $0.03 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.01, with 1.0 analysts recommending between $0.01 and $0.01.
Revenue Estimates
In. The current quarter, 2 analysts expect revenue to total $31.75M. It ranges from a high estimate of $31.9M to a low estimate of $31.6M. As of. The current estimate, Xtant Medical Holdings Inc’s year-ago sales were $31.51MFor the next quarter, 2 analysts are estimating revenue of $28.5M. There is a high estimate of $31.6M for the next quarter, whereas the lowest estimate is $25.4M.
A total of 2 analysts have provided revenue estimates for XTNT’s current fiscal year. The highest revenue estimate was $133.5M, while the lowest revenue estimate was $133.1M, resulting in an average revenue estimate of $133.3M. In the same quarter a year ago, actual revenue was $117.27MBased on 2 analysts’ estimates, the company’s revenue will be $113.4M in the next fiscal year. The high estimate is $125.1M and the low estimate is $101.7M.
